Johnson & Johnson's Janssen Therapeutics reported that the U.S. FDA has approved OLYSIO(TM) (simeprevir), for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
